BERKELEY HEIGHTS, N.J., April 16, 2009 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) announced today the presentation of preclinical data from its two most advanced clinical programs, sapacitabine and seliciclib, at the upcoming American Association of Cancer Research (AACR) Annual Meeting to be held in the Colorado Convention Center in Denver, CO from April 18 - 22, 2009.
